Abstract
ObjectivesThis integrated analysis presents the safety profile of upadacitinib, a Janus kinase inhibitor, at 15 mg and 30 mg once daily in patients with moderately to severely active rheumatoid arthritis...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have